Volume 22 Issue 12, December 2004

Volume 22 Issue 12

The flower of the opium poppy, Papaver somniferum, showing the sexual parts. Allen et al. have used RNA interference to modify the alkaloid content of this poppy (see p. 1559). Credit: Jeremy Burgess/Photo Researchers, Inc.

Editorial

News

  • News |

    The climate for listing on US stock exchanges is less favorable as 2004 reaches its end.

    • Stacy Lawrence
  • News |

    Biotech companies could have their say in setting up standards for regulatory approval of cutting edge drugs, as they benefit from parallel scientific advice from Europe and the US.

    • Alla Katsnelson
  • In Brief

  • News |

    Bioethicist Daniel Callahan argues that, with infinite demand and finite resources, pricey biotech drugs and the present US healthcare system are unsustainable.

    • Stephan Herrera
  • Data Page

  • News Feature

  • News Feature |

    China is a growing biotech player whose main competitive edge lies in low development costs. But will inexperienced money men and a disinterested pharmaceutical industry hold it back? Sabine Louët investigates.

    • Sabine Louët

Opinion and Comment

Feature

News and Views

Research

Resource

Computational Biology

    Perspective

  • Perspective |

    • Helen Jenkins
    • , Nigel Hardy
    • , Manfred Beckmann
    • , John Draper
    • , Aileen R Smith
    • , Janet Taylor
    • , Oliver Fiehn
    • , Royston Goodacre
    • , Raoul J Bino
    • , Robert Hall
    • , Joachim Kopka
    • , Geoffrey A Lane
    • , B Markus Lange
    • , Jang R Liu
    • , Pedro Mendes
    • , Basil J Nikolau
    • , Stephen G Oliver
    • , Norman W Paton
    • , Sue Rhee
    • , Ute Roessner-Tunali
    • , Kazuki Saito
    • , Jørn Smedsgaard
    • , Lloyd W Sumner
    • , Trevor Wang
    • , Sean Walsh
    • , Eve Syrkin Wurtele
    •  & Douglas B Kell

Naturejobs

Erratum

Corrigendum

Supplement